Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

or in the absence of resuscitative equipment.
  • NUCYNTA® ER is contraindicated in any patient who has or is suspected of having a paralytic ileus.
  • NUCYNTA® ER is contraindicated in patients who are receiving monoamine oxidase inhibitors (MAOIs) or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events.
  • NUCYNTA® ER is contraindicated in patients with a known hypersensitivity to the active substance, tapentadol, or any component of the product. Angioedema has been reported in association with use of tapentadol.
  • WARNINGS & PRECAUTIONS

    • NUCYNTA® ER tablets are to be swallowed whole and are not to be split, broken, chewed, dissolved, or crushed. Taking split, broken, chewed, crushed, or dissolved NUCYNTA® ER tablets leads to the rapid release and absorption of a potentially fatal dose of tapentadol. 
    • NUCYNTA® ER tablets must be kept in a secure place out of the reach of children. Accidental consumption of NUCYNTA® ER, especially in children, can result in a fatal overdose of tapentadol.
    • Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.
    • Use NUCYNTA® ER with caution in patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve, such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) dep
      '/>"/>

    SOURCE Janssen Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
    2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
    4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
    5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
    6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
    7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
    8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
    10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
    11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
    (Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
    (Date:5/22/2015)... , May 22, 2015 ... phase clinical research unit with a worldwide reputation ... for its frequent publications in peer reviewed medical ... European stakeholders and regulators in discussions about rules ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
    Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
    ... 2011  FUJIFILM Medical Systems U.S.A., Inc. today announced ... to the company,s Synapse® RIS and Synapse® TeleRIS ... (RSNA) 2011 Annual Meeting. Version 6.1 includes graphical ... to better monitor and manage performance in real ...
    ... Fovia Medical, Inc., a global leader in ... leading provider of healthcare enterprise imaging and information ... enhance its product offering by incorporating Fovia,s High ... zero-download v|Series product lines, including both web-accessible and ...
    Cached Medicine Technology:Latest Version of Fujifilm's Synapse® RIS and TeleRIS Now Available 2Latest Version of Fujifilm's Synapse® RIS and TeleRIS Now Available 3DR Systems Embeds HDVR® in Unity RIS/PACS and Zero-Download v|Series 2DR Systems Embeds HDVR® in Unity RIS/PACS and Zero-Download v|Series 3
    (Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
    (Date:5/22/2015)... May 22, 2015 According to a new ... generations are equally as likely to worry about what will ... Gen X, 77% Boomers, 69% Silent Generation), which may help ... are scared of aging, particularly Millennials (47%), Gen X’ers (51%), ... Poll in April, 2015 among more than 2,000 U.S. adults ...
    (Date:5/22/2015)... 22, 2015 Coco Libre, the Official Coconut ... World Record at the 104th running of the race. On ... luge served 315 people in one hour—one person about every ... is so true to the heart of the Bay Area, ... ice luge to the finish line only made sense,” said ...
    (Date:5/22/2015)... PA (PRWEB) May 22, 2015 According to ... a hub for drug related death, totaling almost 2,500 confirmed ... as reported by state officials, totals 2,489 deaths stemming from ... work out, Pennsylvania loses seven people every day to fatal ... has been singled out as one of the most rife ...
    (Date:5/22/2015)... Gateway Building Concepts is experienced with all ... company specialize in include decks, additions, kitchen remodeling, interior ... much more. , The redesigned logo is a ... company. It includes two geometrical lines that represent the ... to be used with many things associated with the ...
    Breaking Medicine News(10 mins):Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2
    ... sure what spurs need for early treatment , TUESDAY, ... higher levels of education or disability typically need treatment ... study finds. , The study included 413 patients with ... trials of experimental drugs. The patients were assessed at ...
    ... , TROIS-RIVIERES, Quebec, July 14 ... beautiful and vibrant cities in all of Canada, and ... is recognized worldwide and has an international reputation for ... the growing drug problems facing Vancouver,s downtown eastside. "Our ...
    ... compliance, study finds , TUESDAY, July 14 (HealthDay News) -- ... use of a reminder program for women who were due ... Permanente staff checked electronic health records of its 35,000 members ... a mammogram for 20 months. They were sent a postcard ...
    ... , NEW YORK, July 14 NBC Universal communications ... of Senior Vice President, Communications, NBC Universal Women and Lifestyle Entertainment ... Communications. The announcement was made today by Lauren Zalaznick, President of ... report. , , For the last ...
    ... ARDEE, Ireland, July 14 Warner Chilcott Limited (Nasdaq: ... financial results prior to the market opening on Friday, August 7, 2009. ... a press release, the Company will host a conference call for all ... to review the results. To participate in the call, please dial (888) ...
    ... study finds , TUESDAY, July 14 (HealthDay News) -- People ... for heart disease, a U.S. study has found. , The ... home. At physical examinations conducted in 2005 and 2006, the ... in minutes and miles, and the percentage of the journey ...
    Cached Medicine News:Health News:Educated Parkinson's Patients Move to Meds Sooner 2Health News:Crime, Drugs and Health Problems Face Vancouver's Downtown Eastside 2Health News:Reminders Boost Mammography Appointments 2Health News:Hilary Smith Upped to Senior Vice President, Communications, NBC Universal Women & Lifestyle Entertainment Networks 2Health News:Walking, Biking to Work Pays Off 2
    This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
    ... This is the ... with the high density ... loading options. The extra ... minimizes the excitation beam ...
    This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
    Flexible and sensitive fluorescence/luminescence microplate reader for endpoint and kinetic...
    Medicine Products: